Britain's Most Admired No. 5: GlaxoSmithKline, Andrew Witty

Witty took over as GSK's boss two years ago, and has been busy reshaping the pharma giant to take better advantage of emerging markets. To that end, he is shifting focus away from traditional high-margin blockbuster drugs to a lower-margin but more diverse and less risky product portfolio. He has also relaxed the firm's notoriously rigid pricing policy to bring much-needed medicines within the budgets of the developing world. The shift seems to be working - Q3 sales are up 15% to £6.8bn.

by
Last Updated: 09 Oct 2013


--

Find this article useful?

Get more great articles like this in your inbox every lunchtime

Subscribe

Get your essential reading delivered. Subscribe to Management Today